McCulloch Kevin 4
4 · Xeris Biopharma Holdings, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Xeris President Kevin McCulloch Receives RSUs; Shares Withheld
What Happened
Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma (XERS), was granted equity on Jan 30, 2026: 168,463 restricted stock units (RSUs) and 225,225 stock options (derivative award), together covering 393,688 underlying shares. On Jan 31, 2026, 126,062 shares were withheld/disposed to satisfy tax withholding associated with RSU vesting; the withholding was reported at $7.36 per share, generating approximately $927,816. These grants are awards (not open-market purchases or voluntary sales).
Key Details
- Grant dates: Jan 30, 2026 (RSUs and options). Withholding: Jan 31, 2026. Filing date: Feb 2, 2026.
- Withheld/disposed shares: 68,454; 30,289; 27,319 — total 126,062 shares withheld at $7.36/share (total ≈ $927,816).
- Awards: 168,463 RSUs (F1) and 225,225 stock options (derivative, F4). RSUs/options reported as acquired at $0.00.
- Vesting: RSUs vest in equal annual installments over three years (subject to continued employment). Stock options also vest in equal annual installments over three years (F1, F4).
- Shares owned after the transaction: not specified in this filing.
- Footnotes: F2 confirms shares were withheld by the issuer to satisfy tax withholding on net-settled RSUs. F3 notes the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
- Filing timeliness: filed Feb 2, 2026; the filing date is indicated on the Form 4 and no late filing flag is provided.
Context
- This was an equity award and a net-settlement tax withholding, not an open-market sale. Withholding to cover taxes is a common administrative action when RSUs vest and does not necessarily indicate a discretionary sale by the insider.
- The stock options are subject to multi-year vesting and are not yet exercised into freely tradable shares; the RSU withholding reflects vested shares being net-settled.
Insider Transaction Report
Form 4
McCulloch Kevin
See Remarks
Transactions
- Award
Common Stock
[F1]2026-01-30+168,463→ 1,853,889 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−68,454$503,821→ 1,785,435 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−30,289$222,927→ 1,755,146 total - Tax Payment
Common Stock
[F2]2026-01-31$7.36/sh−27,319$201,068→ 1,727,827 total - Award
Stock Option (Right to Buy)
[F4]2026-01-30+225,225→ 225,225 totalExercise: $7.36Exp: 2036-01-30→ Common Stock (225,225 underlying)
Holdings
- 25,000(indirect: By Spouse)
Common Stock
[F3]
Footnotes (4)
- [F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
- [F2]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
- [F3]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F4]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.
Signature
/s/ Beth Hecht, Attorney-in-Fact|2026-02-02